Drug Trial Radar · NCT00366249
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
Last checked: Nov 19, 2026Latest source record: Apr 28, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,061
Actual
Start
Jan 2007
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.
Conditions
- Bacterial Infections
- Diabetic Foot
- Osteomyelitis
Interventions
TigecyclineDrug
150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
ErtapenemDrug
Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Clinical Response of Cure Vs. Failure.Time frame: Test of cure visit (TOC): Assessed at least 12 days post last dose
- Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.Time frame: Test of cure visit (TOC): Assessed at least 12 days post last dose
Locations
211 sites in 39 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Northridge, California
Site not named
San Francisco, California
Site not named
Sylmar, California
Site not named
Torrance, California
Site not named
Orlando, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
West Palm Beach, Florida
Site not named
Honolulu, Hawaii
Site not named
Chicago, Illinois
Site not named
Evanston, Illinois
Site not named
North Chicago, Illinois
Site not named
Springfield, Illinois
Site not named
Springfield, Illinois
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Somers Point, New Jersey
Site not named
Winston-Salem, North Carolina
Site not named
Lima, Ohio
Site not named
Toledo, Ohio
Site not named
West Reading, Pennsylvania
Site not named
Columbia, South Carolina
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Córdoba, Argentina
Site not named
Mendoza, Argentina
Site not named
Buenos Aires, Buenos Aires, Argentina
Site not named
Chivilcoy, Buenos Aires, Argentina
Site not named
Ciudadela, 3 de Febrero, Buenos Aires, Argentina
Site not named
Ciudadela, 3 de Febrero, Buenos Aires, Argentina
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.